Menstrual Health and Cycle Regulation

Menstrual health encompasses the biological, hormonal, and physiological processes governing the uterine cycle, as well as the clinical conditions that arise when those processes are disrupted. This page covers the mechanics of the menstrual cycle, the causal factors behind common irregularities, classification boundaries between normal variation and diagnosable conditions, and the contested clinical terrain around cycle "regulation." Understanding these distinctions is foundational to navigating the broader reproductive health landscape and the regulatory frameworks that shape clinical care.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

Menstrual health refers to the physiological process by which the uterine endometrium cycles through proliferative and secretory phases, culminating in menstruation when fertilization does not occur, as well as the systemic hormonal axis that drives this cycle. The World Health Organization (WHO) defines menstrual health as extending beyond the cycle itself to include access to accurate information, hygienic materials, safe facilities, and freedom from stigma — a framing documented in the WHO's 2022 menstrual health framework.

The scope of clinical concern ranges from benign variation in cycle length to diagnosable disorders including amenorrhea, dysmenorrhea, menorrhagia, and intermenstrual bleeding. In the United States, the clinical standards governing these diagnoses are primarily shaped by guidance from the American College of Obstetricians and Gynecologists (ACOG) and, for pharmaceutical interventions, by the U.S. Food and Drug Administration (FDA). The regulatory context for women's health details how federal oversight applies to diagnostic tools and treatments in this category.

Core mechanics or structure

The menstrual cycle is governed by the hypothalamic-pituitary-ovarian (HPO) axis, a three-tier hormonal feedback system. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses, which stimulates the anterior pituitary to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These two hormones act on the ovaries to drive follicular development and the production of estradiol and progesterone.

A standard cycle is divided into 4 phases:

1. Menstrual phase (days 1–5 in a textbook 28-day cycle): Endometrial lining shed as progesterone and estrogen fall.
2. Follicular phase (days 1–13): Rising FSH stimulates follicular development; estradiol rises and thickens the endometrium.
3. Ovulatory phase (approximately day 14): An LH surge triggers release of a mature oocyte.
4. Luteal phase (days 15–28): The corpus luteum produces progesterone; if implantation does not occur, the corpus luteum degenerates and hormone levels fall, restarting the cycle.

ACOG defines a normal cycle length as 21 to 35 days, with menstrual flow lasting 2 to 7 days and blood loss averaging 30 to 80 milliliters per cycle (ACOG Practice Bulletin No. 128). Cycle length varies physiologically across the reproductive lifespan, with the greatest variability occurring in the 2 years following menarche and the 3 to 5 years preceding menopause.

Causal relationships or drivers

Cycle irregularity arises from disruptions at one or more levels of the HPO axis, or from structural abnormalities of the uterus or ovaries. Major causal categories include:

Hormonal dysregulation: Excess androgens, as seen in polycystic ovary syndrome (PCOS), suppress normal follicular maturation and produce anovulatory cycles. Thyroid dysfunction — both hypothyroidism and hyperthyroidism — interferes with GnRH pulsatility; the American Thyroid Association identifies menstrual irregularity as a recognized symptom of thyroid disease (ATA Clinical Guidelines). Elevated prolactin, from a pituitary adenoma or medications, suppresses the HPO axis and produces amenorrhea.

Structural factors: Uterine fibroids (see uterine fibroids) and endometrial polyps alter blood flow mechanics and can produce heavy or prolonged bleeding. Endometriosis (see endometriosis) does not typically cause irregular cycles but is strongly associated with dysmenorrhea due to prostaglandin-mediated inflammation.

Energy availability: Functional hypothalamic amenorrhea (FHA) results when caloric restriction, excessive exercise, or psychological stress reduces GnRH pulsatility below the threshold required for ovulation. The Female Athlete Triad — a triad of low energy availability, menstrual dysfunction, and low bone density — is documented in the American College of Sports Medicine's (ACSM) evidence-based position statement.

Medications: Hormonal contraceptives suppress endogenous cycling by design. Long-acting reversible contraceptives such as the levonorgestrel IUD produce amenorrhea in approximately 20% of users at 12 months, per FDA-approved prescribing information for Mirena.

Classification boundaries

ACOG's 2011 PALM-COEIN classification system provides the current clinical framework for abnormal uterine bleeding (AUB). The acronym encodes two categories:

• PALM (structural causes): Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia
• COEIN (non-structural causes): Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified

This system replaced older terminology such as "dysfunctional uterine bleeding," which ACOG now considers imprecise. The formal diagnostic boundary between heavy menstrual bleeding (HMB) and normal bleeding is set at greater than 80 milliliters per cycle, though ACOG acknowledges that patient-reported impact on quality of life is clinically significant even when objective loss remains below that threshold.

Classification boundaries also govern age-specific interpretation. Cycles shorter than 21 days or longer than 45 days in adolescents within 1 year of menarche are considered within the range of normal maturation by the American Academy of Pediatrics (AAP), while the same parameters would prompt evaluation in an adult of reproductive age.

Tradeoffs and tensions

Hormonal contraceptives as "cycle regulation": Combined oral contraceptives (COCs) are widely prescribed to manage dysmenorrhea, heavy bleeding, and cycle irregularity. The FDA has approved specific formulations for conditions such as PMDD (e.g., Yaz/drospirenone-containing pills). However, COCs suppress the endogenous HPO axis rather than correcting underlying dysfunction. Clinicians and researchers debate whether prescribing COCs to adolescents masks diagnosable conditions — particularly PCOS and FHA — that warrant distinct management.

Defining "normal" across populations: Research published in the journal npj Digital Medicine using Apple Women's Health Study data demonstrated that cycle length distributions differ across racial and ethnic groups, complicating universal numeric thresholds. Health disparity researchers argue that normative data derived predominantly from white European populations may misclassify cycles in Black and Hispanic women; health disparities in women's health elaborates on this evidentiary gap.

Symptom-driven vs. mechanism-driven diagnosis: Heavy bleeding is a symptom, not a diagnosis. The tension between patient-reported burden and objective measurement is unresolved: ACOG recognizes both quantitative (≥80 mL) and qualitative criteria, but clinical practice rarely involves objective measurement of blood volume, relying instead on validated instruments such as the Pictorial Blood Assessment Chart (PBAC).

Common misconceptions

Misconception: A 28-day cycle is the medical standard.
Correction: 28 days is a historical and statistical mean, not a normative standard. ACOG's published normal range spans 21 to 35 days, and population studies using longitudinal data (including the PRESTO cohort study) show that cycle length varies substantially within individuals across months.

Misconception: Hormonal birth control "regulates" the cycle.
Correction: Withdrawal bleeding on COCs is pharmacologically induced by the hormone-free interval; it is not a physiological menstrual period and does not reflect HPO axis function. Stopping COCs may reveal pre-existing irregularity that was suppressed rather than treated.

Misconception: Painful periods are always normal.
Correction: Primary dysmenorrhea (pain without identified pathology) is common, but secondary dysmenorrhea has identifiable structural causes including endometriosis and adenomyosis. ACOG estimates that endometriosis affects approximately 1 in 10 women of reproductive age, and diagnostic delay averages 7 to 10 years from symptom onset to confirmed diagnosis, per Endometriosis Foundation of America data.

Misconception: Irregular cycles always indicate a serious disorder.
Correction: Cycle variability is physiologically expected at menarche, postpartum, and perimenopause (see perimenopause). Transient irregularity caused by acute illness, travel, or short-term stress does not meet criteria for a clinical diagnosis of ovulatory dysfunction.

Checklist or steps (non-advisory)

The following sequence reflects how clinical evaluation of menstrual irregularity is typically structured, based on ACOG and ACSM published frameworks. This is a descriptive reference, not clinical guidance.

1. Establish baseline cycle history: Document cycle length, duration, flow volume estimates, and symptom pattern over a minimum of 3 cycles.
2. Screen for structural causes: Pelvic ultrasound is the first-line imaging modality per ACOG for evaluating AUB; identifies fibroids, polyps, and ovarian pathology.
3. Assess hormonal axis: Laboratory evaluation includes FSH, LH, estradiol, prolactin, TSH, and androgens (total testosterone, DHEA-S) to localize HPO axis disruption.
4. Evaluate energy availability: In athletes or individuals with restricted intake, assessment of nutritional status and bone density (DXA scan) is recommended per ACSM Female Athlete Triad consensus.
5. Apply PALM-COEIN classification: Assign provisional structural or non-structural category to guide differential diagnosis.
6. Document impact on quality of life: Use validated instruments (PBAC, Menorrhagia Multi-Attribute Scale) as ACOG acknowledges subjective burden as a clinical criterion.
7. Consider endometrial sampling: ACOG recommends endometrial biopsy for women over age 45 with AUB, or at any age with risk factors for endometrial hyperplasia, to rule out malignancy (see uterine and endometrial cancer).

Reference table or matrix

References

• World Health Organization — Menstrual Health Framework (2022)
• American College of Obstetricians and Gynecologists (ACOG) — Practice Bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding
• American College of Obstetricians and Gynecologists — PALM-COEIN Classification System
• American Thyroid Association — Clinical Practice Guidelines
• American College of Sports Medicine — Female Athlete Triad
• Endometriosis Foundation of America — Diagnostic Delay Data
• U.S. Food and Drug Administration — Approved Drug Products (Mirena, Yaz)
• American Academy of Pediatrics — Menstruation in Girls and Adolescents
• Women's Health Authority — Home

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)